Assessment of 2022 European LeukemiaNet risk classification system in real‐world cohort from China

Abstract

AbstractBackgroundThe European LeukemiaNet (ELN) risk classification system for acute myeloid leukemia (AML) patients has been used worldwide. In 2022, the ELN risk classification system modified risk genes including CEBPA mutation status, myelodysplasia‐related (MR) gene mutations and internal tandem duplications of FLT3 (FLT3‐ITD).MethodsWe include newly diagnosed de novo AML patients at our center from January 2017 to December 2021, regardless of the further treatment received. Clinical data and date of survival were included. Survival analysis were performed using the Kaplan–Meier method, and the log‐rank test was used to compare survival between different risk groups.ResultsWe include 363 newly diagnosed de novo AML patients from 2017 to 2021 to assess the accuracy of the ELN risk classification system. Their survival results show that the ELN‐2022 risk classification system is not superior to the ELN‐2017 version; for patients with FLT3‐ITD mutations but without FLT3 inhibitor treatment, their survival is similar to the ELN‐2022 adverse risk group. The ELN‐2022 risk classification system cannot accurately clarify ECOG performance status (PS) 2–4 patients, especially in the ELN‐2022 favorable risk group.ConclusionThe ELN‐2022 risk stratification system may not be appropriate for patients unable to receive intensive therapy or FLT3 inhibitor; more real‐world data is needed to straify patients with worse ECOG PS and inferior intensive therapy.